Moussallem Toufic, Lim Chetana, Osseis Michael, Esposito Francesco, Lahat Eylon, Fuentes Liliana, Salloum Chady, Azoulay Daniel
Department of Hepato-Biliary and Pancreatic Surgery and Liver Transplantation, AP-HP Henri Mondor Hospital.
Drug Discov Ther. 2017 Nov 22;11(5):291-292. doi: 10.5582/ddt.2017.01039. Epub 2017 Oct 11.
In patients with malignancy who receive aflibercept based chemotherapy, gastrointestinal perforation is among the reported adverse events with a prevalence of 1.9%. This complication may lead to mortality up to 10.8%. We here report a case of small bowel perforation that occurred fifteen days after the first cycle of aflibercept in a 58-year old female who had metachronous colorectal liver metastases. Emergency laparotomy was performed and revealed a small bowel perforation without any anastomotic dehiscence. Surgery was followed by uneventful outcome. The use of aflibercept in patients with malignancy may be associated with very early gastrointestinal perforation and this should be known by oncologist and surgeons.
在接受阿柏西普化疗的恶性肿瘤患者中，胃肠道穿孔是报告的不良事件之一，发生率为1.9%。这种并发症可能导致高达10.8%的死亡率。我们在此报告一例58岁女性患者，该患者有异时性结直肠肝转移，在接受阿柏西普第一周期化疗15天后发生小肠穿孔。进行了急诊剖腹手术，发现小肠穿孔，无任何吻合口裂开。手术后恢复顺利。恶性肿瘤患者使用阿柏西普可能与非常早期的胃肠道穿孔有关，肿瘤学家和外科医生应该了解这一点。
